<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo>, the leading cause of disability, lacks treatment beyond thrombolysis </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0011009'>acute</z:hpo> injection of human mesenchymal stem cells (hMSCs) provides a benefit which could be mediated by an enhancement of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>A clinical autologous graft requires an hMSC culture delay incompatible with an <z:hpo ids='HP_0011009'>acute</z:hpo> administration </plain></SENT>
<SENT sid="3" pm="."><plain>This study evaluates the cerebral microvascular changes after a delayed injection of hMSCs </plain></SENT>
<SENT sid="4" pm="."><plain>At day 8 after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo), two groups of rats received an intracerebral injection in the damaged brain of either 10 μL of cell suspension medium (MCAo-PBS, n = 4) or 4 × 10⁵ hMSCs (MCAo-hMSC, n = 5) </plain></SENT>
<SENT sid="5" pm="."><plain>Two control groups of healthy rats underwent the same injection procedures in the right hemisphere (control-PBS, n = 6; control-hMSC, n = 5) </plain></SENT>
<SENT sid="6" pm="."><plain>The effect of hMSCs on the microvasculature was assessed by MRI using three parameters: apparent diffusion coefficient (<z:chebi fb="49" ids="35181">ADC</z:chebi>), cerebral blood volume (CBV) and vessel size index (VSI) </plain></SENT>
<SENT sid="7" pm="."><plain>At day 9, eight additional rats were euthanised for a histological study of the microvascular parameters (CBV, VSI and vascular fraction) </plain></SENT>
<SENT sid="8" pm="."><plain>No <z:chebi fb="49" ids="35181">ADC</z:chebi> difference was observed between MCAo groups </plain></SENT>
<SENT sid="9" pm="."><plain>One day after intracerebral injection, hMSCs abolished the CBV increase observed in the lesion (MCAo-hMSC: 1.7 ± 0.1% versus MCAo-PBS: 2.2 ± 0.2%) and delayed the VSI increase (vasodilation) secondary to <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Histological analysis at day 9 confirmed that hMSCs modified the microvascular parameters (CBV, VSI and vascular fraction) in the lesion </plain></SENT>
<SENT sid="11" pm="."><plain>No <z:chebi fb="49" ids="35181">ADC</z:chebi>, CBV or VSI differences were observed between control groups </plain></SENT>
<SENT sid="12" pm="."><plain>At the <z:hpo ids='HP_0001297'>stroke</z:hpo> post-<z:hpo ids='HP_0011009'>acute</z:hpo> phase, hMSC intracerebral injection rapidly and transiently modifies the cerebral microvasculature </plain></SENT>
<SENT sid="13" pm="."><plain>This microvascular effect can be monitored in vivo by MRI </plain></SENT>
</text></document>